Karsten Meisloch

Part of Takeda Pharmaceutical Co., Ltd., Shire Deutschland GmbH develops therapies for patients with rare and other specific diseases. The company is based in Berlin, Germany. The CEOs are Uwe Fröhlich, Heidrun Irschik-Hadjieff, Karsten Meisloch. The German company was founded in 1986.

Shire Orphan Therapies GmbH engages in the development, manufacture, and distribution of chemical and biochemical products, ingredients, as well as pharmaceutical and diagnostic products. The company was founded in 1994 and is headquartered in Berlin, Germany.

Part of Takeda Pharmaceutical Co., Ltd., Shire Deutschland GmbH develops therapies for patients with rare and other specific diseases. The company is based in Berlin, Germany. The CEOs are Uwe Fröhlich, Heidrun Irschik-Hadjieff, Karsten Meisloch. The German company was founded in 1986.

Part of Takeda Pharmaceutical Co., Ltd., Shire Deutschland GmbH develops therapies for patients with rare and other specific diseases. The company is based in Berlin, Germany. The CEOs are Uwe Fröhlich, Heidrun Irschik-Hadjieff, Karsten Meisloch. The German company was founded in 1986.

Shire Orphan Therapies GmbH engages in the development, manufacture, and distribution of chemical and biochemical products, ingredients, as well as pharmaceutical and diagnostic products. The company was founded in 1994 and is headquartered in Berlin, Germany.

Shire Orphan Therapies GmbH engages in the development, manufacture, and distribution of chemical and biochemical products, ingredients, as well as pharmaceutical and diagnostic products. The company was founded in 1994 and is headquartered in Berlin, Germany.

Shire Orphan Therapies GmbH engages in the development, manufacture, and distribution of chemical and biochemical products, ingredients, as well as pharmaceutical and diagnostic products. The company was founded in 1994 and is headquartered in Berlin, Germany.